Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI takes aim at pancreatic cancer: can it forecast chemotherapy outcomes?

NCT ID NCT07803770

Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This observational study tests whether artificial intelligence can predict how well pancreatic cancer responds to chemotherapy and how the disease may progress. Researchers will analyze data from 700 patients, including endoscopic ultrasound images, CT/MRI scans, lab results, and tissue samples. They will build and validate AI models that combine these data sources to forecast treatment response and survival. The goal is to develop a tool that helps doctors personalize treatment for pancreatic cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence models analyzing endoscopic ultrasound, CT/MRI, and pathology data
What this could lead to
If successful, this could lead to AI tools that help doctors predict how well a patient's pancreatic cancer will respond to chemotherapy, guiding more personalized treatment decisions.
What could go wrong
This is an observational study, not a treatment trial. The AI models are being developed and tested for accuracy, and they may not perform well enough in real-world settings or across different patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients who underwent EUS at the Pancreato-Biliary Endoscopy and Endoscopic Ultrasound Unit of IRCCS San Raffaele Hospital with an histological diagnosis of PDAC.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologically confirmed diagnosis (final pathology report) of pancreatic cancer obtained through endoscopic ultrasound-guided tissue sampling (EUS-FNA or EUS-FNB) * Age ≥ 18 years at the time of diagnosis * Minimum follow-up duration of 6 months after diagnosis * Absence of other concomitant neoplastic diseases * Age\>= 18 years * Capacity to understand and make informed decisions * Written informed consent provided by the patient Exclusion Criteria: * All patients who underwent endoscopic ultrasound with tissue sampling at the Pancreato-Biliary Endoscopy and Endoscopic Ultrasound Unit of IRCCS San Raffaele Hospital but do not meet the inclusion criteria will be excluded from the final analysis cohorts. * Age\<18 years * Inability to understand and make informed decisions * Refusal to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence (AI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence (AI) Endoscopic ultrasound (EUS) Pancreatic ductal adenocarcinoma (PDAC) Pancreatic neoplasms Radiomics

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Ospedale San Raffaele

    Milan, Lombardy, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.